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Abstract 
Background: The aim of this study was to determine if the diagnostic performance of breast 
lesion examinations could be improved by using both digital breast tomosynthesis (DBT) and 
conventional digital mammography (CDM). 
Methods: Our institutional review board approved the protocol, and patients were provided 
the opportunity to opt out of the study. A total of 628 patients aged 22 to 91 years with abnormal 
screening results or clinical symptoms were consecutively enrolled between June 2015 and 
March 2016. All patients underwent DBT and CDM, and 1164 breasts were retrospectively 
analyzed by three radiologists who interpreted the results based on the Breast Imaging 
Reporting and Data System. Categories 4 and 5 were considered positive, and pathological 
results were the gold standard. The diagnostic performance of CDM and CDM plus DBT was 
compared using the mean areas under the receiver operating characteristic (ROC) curves. 
Results: A total of 100 breast cancer cases were identified. The areas under the ROC curves 
were 0.9160 (95% confidence interval, 0.8779–0.9541) for CDM alone and 0.9376 (95% 
confidence interval, 0.9019–0.9733) for CDM plus DBT. The cut-off values for both CDM 
alone and CDM plus DBT measurements were 4, with sensitivities of 61.0% (61/100) and 
83.0% (83/100), respectively, and specificities of 99.1% (1054/1064) and 98.9% (1052/1064), 
respectively. CDM yielded 39 false-negative diagnoses, while CDM plus DBT identified breast 
cancer in 22 of those cases (56.4%).  
Conclusion: The combination of DBT and CDM for the diagnosis of breast cancer in women 
with abnormal examination findings or clinical symptoms proved effective and should be used 
to improve the diagnostic performance of breast cancer examinations. 
 
Keywords: Breast cancer, conventional digital mammography, digital breast tomosynthesis, 
false negative, screening 
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Abbreviations: BI-RADS: Breast Imaging Reporting and Database System; CDM: 
conventional digital mammography; DBT: digital breast tomosynthesis; ROC: receiver 
operating characteristic. 
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Introduction 
Conventional digital mammography (CDM) is widely used to screen for breast 
cancer and examine breast lesions [1-7]. However, CDM is limited by its inability to accurately 
distinguish suspicious lesions from adjacent overlapping tissue. Specifically, diagnosis 
becomes more challenging in instances of dense or heterogeneously dense breasts in terms of 
sensitivity and specificity [8, 9]. In Asian countries, including Japan, women’s breasts are 
relatively small and highly dense [10, 11]. 
Digital breast tomosynthesis (DBT) is a three-dimensional imaging technique 
developed to overcome some of the limitations of CDM. During DBT, an X-ray tube moves 
through a limited arc angle and rebuilds the tissue in a series of thin slices to minimize the 
influences of breast tissue overlapping and structural noise [12]. Several studies have shown 
that DBT is a promising tool for breast cancer screening, as it is associated with decreased 
screening recall rates, increased cancer detection rates, and positive predictive values [13, 14]. 
While DBT has been extensively investigated, most previous studies have evaluated 
its use in screening programs [15, 16], while only a few have investigated its role in examining 
actual breast lesions. If DBT can resolve diagnostic difficulties of CDM caused by breast tissue 
overlapping structures and structural noise, then DBT would be useful for both screening and 
examinations. Therefore, the aim of this study was to determine if the diagnostic performance 
of breast lesion examinations could be improved by jointly using DBT and CDM for breast 
lesion examinations. 
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Materials and Methods 
Study population 
The study protocol was approved by our institutional review board, and the opt-out 
model (via website) was used. Patients were consecutively recruited between June 2015 and 
March 2016. Patients who had not undergone previous mammography at our hospital were 
enrolled in this study. Data were interpreted retrospectively. Patients with suspected 
malignant findings underwent fine-needle or core biopsy followed by surgery and 
histopathological examination of the specimens. Patients without suspected malignant 
findings were followed for at least 12 months to establish the absence of cancer. If patients 
had a previous mastectomy, breast implants (including in the opposite breast), or previous 
breast cancer treatment, they were further excluded from analysis because of the effects these 
procedures can have on breast architecture. Men were also excluded. Ultimately, 1164 breasts 
(628 patients; age range: 22–91 years; mean age: 50.2 years) were evaluated. 
 
Image acquisition 
Both CDM and DBT images were obtained using a commercially available system 
(Senographe Essential; GE Healthcare Japan, Tokyo, Japan). The detector used in this system 
was an amorphous silicon flat-panel detector. The CDM and DBT images were acquired 
using a tube anode/filter combination (Mo/Mo, Mo/Rh, Rh/Rh) as determined by the 
automatic exposure control of the unit. Nine projections images were obtained with a total 
tomosynthesis angle of 25°, acquired in step-and-shoot mode while the breast was 
compressed in the fixed position. Using this machine, the mean radiation dose for DBT in 
both breasts in a single view was approximately 1.47 mGy. All patients concurrently 
underwent DBT in one view (medial lateral oblique) and CDM in two views (craniocaudal 
and medial lateral oblique). DBT examination was performed immediately after CDM by the 
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same designated technician. CDM and DBT images were obtained in the same compression 
mode using automatic exposure control. 
Image review  
DBT images were reconstructed using the successive approximation method and 
divided into thin 0.5-mm slices and thick 10-mm slabs for viewing on a workstation. Three 
radiologists, who read at least 1,000 CDM studies and 300 DBT studies per year combined, 
interpreted both the CDM and DBT images on 8 MG monitors. Each radiologist first 
evaluated the CDM image while blinded to the DBT image and the patient’s clinical 
information, and assigned a Breast Imaging Reporting and Database System (BI-RADS) 
category [17]. The radiologist then evaluated the DBT image and assigned a BI-RADS 
category to that as well. When the assigned BI-RADS categories differed among the 
radiologists, a consensus was reached through discussion. 
BI-RADS categories 1, 2, and 3 were identified as negative, while categories 4 and 
5 were identified as positive. The pathological findings from surgery and biopsy were used as 
the gold standard for the diagnosis of breast cancer. Lesions such as fibroadenoma and breast 
cysts that did not appear to change on ultrasonography during an observation period of at 
least 12 months were identified as benign lesions.  
Statistical analysis  
The overall comparison of clinical performance was derived from the differences 
between the mean areas under the receiver operating characteristic (ROC) curves. Fisher’s 
exact test was used to compare the sensitivity, specificity, positive predictive value, and 
negative predictive value. A p-value < 0.05 was considered statistically significant. 
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Results 
In this study, of the 1164 breasts analyzed, 100 breasts were found to have cancer. 
Biopsy was performed in 226 of 1164 cases. Of the cancers, 74 were invasive ductal 
carcinomas, 19 were ductal carcinomas in situ, 4 were invasive lobular carcinomas, 1 was a 
mucinous carcinoma, and 1 was an apocrine carcinoma. Histological diagnosis was unknown 
in 1 case because the patient was diagnosed with breast cancer via biopsy but switched hospitals 
afterwards; therefore, her postoperative histological results were not available. Comparison of 
categories of all breasts and all carcinoma cases is presented in Table 1. The percentage of 
dense breasts (i.e., extremely dense or heterogeneously dense) was 85.1% (990/1164), and that 
of scattered or fatty breasts was 14.9% (174/1164).  
ROC curves of CDM alone and CDM plus DBT 
The areas under the ROC curves were 0.916 (95% confidence interval, 0.878–0.954) 
for CDM alone and 0.938 (95% confidence interval, 0.902–0.973) for CDM plus DBT. Using 
BI-RADS category 4 as a cut-off for diagnosing breast cancer in both CDM alone and CDM 
plus DBT, breast tumors were diagnosed with sensitivities of 61.0% (61/100) and 83.0% 
(83/100), specificities of 99.1% (1054/1064) and 98.9% (1052/1064), positive predictive 
values of 85.9% (61/71) and 87.4% (83/95), and negative predictive values of 96.4% 
(1054/1093) and 98.4% (1052/1069), respectively (Figure 1). Sensitivity was significantly 
higher in CDM plus DBT than in CDM alone (p = 0.0009). No significant differences were 
observed in the specificity, positive predictive value, or negative predictive value between 
CDM plus DBT and CDM alone. There were no adverse events. 
Improvement in diagnostic performance by adding DBT 
CDM alone yielded 39 false-negative diagnoses. With the inclusion of DBT, breast 
cancer was diagnosed in 56.4% of these cases (22/39). Of the 22 lesions, 15 were invasive 
ductal carcinomas, 5 were ductal carcinoma in situ lesions, 1 was invasive lobular lesion, and 
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1 was mucinous carcinoma. The descriptions of the findings are shown in Table 2 and Figures 
2–4. Regarding breast density, 86.4% (19/22) of the breasts were dense and 13.6% (3/22) were 
scattered or fatty. 
False-negative cases by CDM plus DBT 
CDM plus DBT failed to diagnose cancer in 17 cases, of which 7 were invasive 
ductal carcinomas, 9 were ductal carcinomas in situ, and 1 was an invasive lobular carcinoma. 
Regarding breast density, 82.4% (14/17) of the breasts were dense and 17.6% (3/17) were 
scattered or fatty. The pathological types of carcinoma are listed in Table 3. Eight cases were 
miscategorized as BI-RADS category 3 by both CDM alone and CDM plus DBT: 7 as 
calcifications and 1 as a mass. These lesions were suspected of being malignant by 
ultrasonography after CDM, follow-up CDM, or ultrasonography, and were subsequently 
verified as such. 
False-positive cases   
CDM plus DBT yielded false-positive diagnoses in 12 cases. In 2 of these cases, the 
CDM findings were considered negative, although the DBT images showed indistinct masses 
and were considered positive. Ultimately, these lesions were deemed to be benign on follow-
up ultrasonography or fine-needle aspiration. As for the other 10 cases that were diagnosed as 
false-positive on both CDM alone and CDM plus DBT, calcification observed in 9 cases was 
diagnosed as mastopathy or benign lesions upon follow-up ultrasonography or biopsy. One 
case with an indistinct mass was proven to be a benign phyllodes tumor following surgery. 
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Discussion 
This study demonstrated an improvement in breast cancer diagnostic performance 
with the combined use of CDM and DBT. When CDM and DBT were combined, the false-
negative rate decreased and sensitivity increased as compared to using only CDM (61.0% to 
83.0%). However, the area under the ROC curve for CDM alone was already high (0.916), and 
was therefore not significantly different from that for CDM plus DBT (0.938). DBT is 
particularly useful for detecting breast cancer with mass formation because DBT shows the 
tumor contour more precisely and increases the tumor’s contrast in comparison to normal 
mammary tissue [18]. Since DBT provides a definite depiction of a lesion, the method should 
be able to distinguish between benign and malignant lesions. In the current study, DBT 
contributed to the discovery of 22 carcinomas, suggesting DBT is a helpful tool for 
discriminating between tumors and normal mammary gland tissue in dense breasts [19]. 
Consequently, we expect that adding DBT is beneficial for Japanese women who have dense 
breasts or a symptom of breast mass. Furthermore, including DBT facilitates the detection of 
focal asymmetries and lesions with architectural distortions, which are often observed in breast 
cancer. 
The ability of DBT to assess calcification has not been established [20–22]. In the 
current study, DBT was not inferior to CDM for the detection of calcified lesions. In addition, 
DBT exhibited a clearer spatial distribution of calcifications in the mammary ducts as 
compared to CDM (Figure 4). Therefore, this study showed that DBT might also be useful for 
the assessment of calcifications in some cases. These advantages contribute to a reduction in 
unnecessary biopsies and subsequently alleviate patients’ mental and economic burdens. 
Further, these advantages improve the confidence of the radiologist’s diagnosis. Previous 
studies have indicated that DBT reduces the number of category 3 cases, which comprise the 
majority of cases with focal asymmetries [22]. In contrast, in the present study, adding DBT 
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increased the number of cases with category 3 (Table 1), including 58 mass lesions with a clear 
margin, suggesting benign lesions. Finally, these were diagnosed as cysts (38), fibroadenomas 
or mastopathies (18), and intraductal papillomas (2) by ultrasonography and biopsy. This is 
considered a reason for the increase of category 3 cases. 
This study had several limitations. First, since our hospital is not a screening facility, 
but a facility that conducts scrutiny and treatment, most patients that were included in this study 
presented with some symptoms or abnormalities in screening mammography. Further, only the 
patients who underwent mammography for the first time at our hospital were selected. Thus, 
some degree of selection bias could not be avoided. Finally, the number of patients was relative 
small in comparison to other screening studies [23, 24].  
Conclusion 
This study demonstrated that the combination of DBT and CDM for the diagnosis 
of breast cancer in women with abnormal screening findings or clinical symptoms proved 
effective and should be used to improve the diagnostic performance of breast cancer 
examination and investigate patients with abnormal findings or those who present with 
clinical symptoms. 
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Figure Legends
 
 
Figure 1 
Receiver operating characteristics curves for (a) conventional digital mammography alone 
and (b) conventional digital mammography plus digital breast tomosynthesis. 
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Figure 2 
A 37-year-old woman with invasive ductal carcinoma. (a) A CDM image shows focal 
asymmetries in the upper portion of the right breast in the MLO view; and (b) a DBT image 
shows an irregular mass with a spiculated margin in the corresponding area of right breast. 
CDM, conventional digital mammography; DBT, digital breast tomosynthesis; MLO, 
mediolateral oblique 
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Figure 3  
A 54-year-old woman with invasive ductal carcinoma. (a) No lesion is detected on the CDM 
image. (b) DBT shows irregular mass with architectural distortion in the middle portion of 
the right breast in the MLO view. 
CDM, conventional digital mammography; DBT, digital breast tomosynthesis; MLO, 
mediolateral oblique 
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Figure 4 
A 68-year-old woman with ductal carcinoma in situ. (a) A CDM image shows grouped 
microcalcifications in the lower portion of the left breast in the MLO view. (b) A DBT image 
shows microcalcifications arrayed in a line. 
CDM, conventional digital mammography; DBT, digital breast tomosynthesis; MLO, 
mediolateral oblique 
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Tables 
Table 1. Comparison of BI-RADS categories using CDM alone vs. CDM plus DBT for all 
cases (a) and all carcinoma cases (b) 
(a) all cases 
 
 
 
 
 
 
 
 
 
 
(b) all carcinoma cases 
 
CDM plus DBT category 
 
1 or 2 3 4 5 Total 
C
D
M
 a
lo
n
e
 c
a
te
g
o
ry
 
1 or 2 869 61 1 1 932 
3 23 116 22 0 161 
4 0 0 33 9 42 
5 0 0 0 29 29 
Total 892 177 56 39 1164 
CDM plus DBT 
 1 or 2 3 4 5 Total 
C
D
M
 a
lo
n
e 
1 or 2 9 0 1 1 11 
3 0 8 20 0 28 
4 0 0 23 9 32 
5 0 0 0 29 29 
Total 9 8 44 39 100 
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BI-RADS, Breast Imaging Reporting and Database System; CDM, conventional digital 
mammography; DBT, digital breast tomosynthesis 
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Table 2. Improvement in diagnostic performance by including DBT 
 
BI-RADS, Breast Imaging Reporting and Database System; CDM, conventional digital 
mammography; DBT, digital breast tomosynthesis; IDC, invasive ductal carcinoma; DCIS, 
ductal carcinoma in situ; ILC, invasive lobular carcinoma; MC, mucinous carcinoma. 
  
CDM alone 
BI-RADS Category 1,2,3 
CDM+DBT 
BI-RADS Category 4,5 
Number 
 
Pathological 
type 
Number 
 
 Mass   
Focal asymmetries Irregular mass  8 
IDC 
DCIS 
ILC 
MC 
4 
2 
1 
1 
Mass  
(suspected as benign) 
Mass  
(suspicion for malignancy) 
4 IDC 4 
Calcification  
(suspected as benign) 
Calcifications +  
irregular mass 
1 IDC 1 
Occult Irregular mass with distortion 1 IDC 1 
 Architectural distortion   
Focal asymmetries Architectural distortion 2 IDC 2 
Suspect architectural distortion Architectural distortion 1 IDC 1 
Occult  Architectural distortion 1 DCIS 1 
 Calcifications   
Calcifications 
(suspected as benign) 
Calcifications  
(suspicion for malignancy) 
3 
IDC 
DCIS 
1 
2 
Focal asymmetries 
Focal asymmetries + 
calcifications 
1 IDC 1 
  
22 
Table 3. Pathological type of false negative cases by CDM+DBT (n = 17) 
CDM alone 
BI-RADS Category 
CDM+DBT 
BI-RADS Category 
Pathological type Number 
1 or 2 1 or 2 IDC 3 
DCIS 5 
ILC 1 
3 3 IDC 4 
DCIS 4 
BI-RADS, Breast Imaging Reporting and Database System; CDM, conventional digital 
mammography; DBT, digital breast tomosynthesis; IDC, invasive ductal carcinoma; DCIS, 
ductal carcinoma in situ; ILC, invasive lobular carcinoma. 
 
 
 
